Quick Answer
Neurogene Inc. reported Total Revenue of $0.00 for fiscal year 2025.
Neurogene Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$925.0K | $0.00 | — | — | — |
| Revenue (ASC 606) | $0.00 -100.0% |
$925.0K | $0.00 | — | — | — |
| Net Income | -$90.35M -20.2% |
-$75.14M -106.9% |
-$36.32M +34.2% |
-$55.19M +9.1% |
-$60.69M -82.4% |
-$33.28M +52.1% |
| Diluted EPS | -$4.24 +0.9% |
-$4.28 -246.1% |
$2.93 +381.7% |
-$1.04 +5.5% |
-$1.10 -71.9% |
-$0.64 |
| Total Assets | $288.60M -14.0% |
$335.73M +50.8% |
$222.57M +103.7% |
$109.27M -33.1% |
$163.26M -22.4% |
$210.52M +43.2% |
| Cash and Equivalents | $103.84M -24.0% |
$136.59M -7.8% |
$148.21M +80.7% |
$82.02M -42.4% |
$142.47M -26.0% |
$192.56M +34.6% |
| Stockholders Equity | $264.89M -14.7% |
$310.38M +66.8% |
$186.02M +227.6% |
-$145.74M -58.6% |
-$91.88M -148.0% |
$191.22M +35.0% |
| R&D Expense | $75.01M +23.1% |
$60.92M +37.2% |
$44.39M -6.5% |
$47.51M +21.3% |
$39.16M | — |
| Operating Income | -$103.33M -25.1% |
-$82.61M -48.6% |
-$55.58M +1.7% |
-$56.52M +6.9% |
-$60.70M -80.0% |
-$33.73M +52.5% |
| Shares Outstanding | 15.49M +4.3% |
14.85M +15.8% |
12.82M | 0 -100.0% |
42.46M +0.6% |
42.20M +11.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | — |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$20.95M | -3.6% | +4.8% |
| Diluted EPS | September 30, 2025 | -$0.99 | +16.8% | +5.7% |
| Total Assets | September 30, 2025 | $287.83M | +75.4% | -3.2% |
| Cash and Equivalents | September 30, 2025 | $71.00M | +6.6% | +20.7% |
| Stockholders Equity | September 30, 2025 | $265.54M | +93.2% | -2.8% |
| R&D Expense | September 30, 2025 | $17.24M | +5.9% | -11.0% |
| Operating Income | September 30, 2025 | -$23.80M | -7.3% | +8.8% |
| Shares Outstanding | September 30, 2025 | 14.78M | +13.6% | +3.5% |
- Neurogene Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- Neurogene Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Neurogene Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Neurogene Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Neurogene Inc. reported Net Income of -$90.35 million for fiscal year 2025.
- Neurogene Inc. showed a decrease of -20.2% in Net Income compared to the prior fiscal year.
- Neurogene Inc. reported Diluted EPS of $4.24 per share (loss) for fiscal year 2025.
- Neurogene Inc. showed an increase of +0.9% in Diluted EPS compared to the prior fiscal year.
- Neurogene Inc. reported Total Assets of $288.60 million for fiscal year 2025.
- Neurogene Inc. showed a decrease of -14.0% in Total Assets compared to the prior fiscal year.
- Neurogene Inc. reported Cash and Equivalents of $103.84 million for fiscal year 2025.
- Neurogene Inc. showed a decrease of -24.0% in Cash and Equivalents compared to the prior fiscal year.
- Neurogene Inc. reported Stockholders Equity of $264.89 million for fiscal year 2025.
- Neurogene Inc. showed a decrease of -14.7% in Stockholders Equity compared to the prior fiscal year.
- Neurogene Inc. reported R&D Expense of $75.01 million for fiscal year 2025.
- Neurogene Inc. showed an increase of +23.1% in R&D Expense compared to the prior fiscal year.
- Neurogene Inc. reported Operating Income of -$103.33 million for fiscal year 2025.
- Neurogene Inc. showed a decrease of -25.1% in Operating Income compared to the prior fiscal year.
- Neurogene Inc. reported Shares Outstanding of 15.49 million shares for fiscal year 2025.
- Neurogene Inc. showed an increase of +4.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: